ELI LILLY WKN: 858560 ISIN: US5324571083 Forum: Aktien Thema: Hauptdiskussion

$HIMS CEO ANDREW DUDUM ON THE DEAL WITH ELI LILLY $LLY "Lilly is one of the most innovative pharmaceutical companies in history, and I’m incredibly proud that Hims & Hers is a part of making sure more people can access the medicines they’ve created." "By working together, we’re not just reaching more people with obesity with seamless, personal access to FDA-approved Lilly medicine. We’re showing the industry what innovators can achieve for customers everywhere when we work together to make the world well."

War aber relativ harmlos. Bin positiv überrascht

ELI LILLY $LLY IS PARTNERING WITH HIMS & HERS $HIMS TO SELL ITS WEIGHT-LOSS DRUGS Hims customers will be able to get Lilly's obesity drugs at discounted cash prices directly through the platform, per Bloomberg. - Foundayo, Lilly's new weight-loss pill: from $149 a month - Zepbound: from $299 a month

...da hab ich's wohl verschrien...

🥺jetzt kapituliert auch Lilly

...unglaublich; alles rot und Eli steigt und steigt...

$1450

Beim Rheumatology Congress vom 06.-11.11. werden vorangeschrittene Studien gegen Arthrose und Arthritis vorgestellt. Könnte den Kurs weiter nach oben ziehen

RBC $ 1600, JPM $ 1650, Morgan Stanley $ 1600, Scotiabank $ 1610; da geht noch was 🙂

DummPot heute grün +0.35% 😯trotz tech inferno...danke Lilly, Pfizer, et al

UBS Maintains Eli Lilly at Buy with $1,625 PT on Obesity Growth and Earnings Momentum

BMO Capital 𝗺𝗮𝗶𝗻𝘁𝗮𝗶𝗻𝘀 𝗢𝘂𝘁𝗽𝗲𝗿𝗳𝗼𝗿𝗺 on 𝗘𝗹𝗶 𝗟𝗶𝗹𝗹𝘆 𝗮𝗻𝗱 𝗖𝗼𝗺𝗽𝗮𝗻𝘆, raises PT to $𝟭𝟲𝟱𝟬 from $𝟭𝟰𝟬𝟬

1400 Dollar 🤩

Unglaublich 😊

👏👏👏

ELI LILLY $LLY Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $24.4B (Est. $22.61B) 🟢; +39% YoY 🔹 Adj. EPS: $7.48; +7% YoY 🔹 Gross Margin: 84.4% 🔹 Mounjaro Revenue: $10.7B; +65% YoY FY26 Guide: 🔹 Revenue: $91.0B-$92.0B (Est. $88.85B) 🟢; from $85B-$87B 🔹 EPS: $35.00-$36.00; from $35.50-$36.50 🔹 Performance Margin: 52.0%-52.5%; from 49.0%-50.5% 🔹 Tax Rate: 19%-20%; from 18%-19%